Focus:
Comment
-
2 September 2019
Success for AstraZeneca’s heart failure therapy Farxiga
AstraZeneca announced the success of its heart failure treatment Farxiga. This trial success could pave the way for a new treatment strategy in HF, helping to fulfil the multiple unmet...
-
2 September 2019
Market growth in prostate cancer largely attributed to label expansions
GlobalData examines competition between prostate cancer therapies, amidst predictions of the market's expansion.
-
30 August 2019
First neuromodulation device for heart failure gains FDA approval
Minnesota-based CVRx has won FDA approval for the first neuromodulation device designed for the treatment of heart failure and high blood pressure.
-
29 August 2019
TAVI procedure volume poised to spike
Transcatheter aortic valve implantation (TAVI) is a relatively new procedure for the minimally invasive replacement of a patient’s aortic valve. In recent years, TAVI has exploded as an extremely successful...
-
28 August 2019
Opportunities and challenges in China’s wound care market
Globally, millions of people suffer from trauma and burns as a result of accidents, natural disasters and violence. Mirroring global trends, wound therapies have steadily advanced to treat patients more...
-
28 August 2019
Bariatric surgery is driving factor for medical tourism
Bariatric surgery - referring to medical procedures intended to result in weight loss - is a growing industry. The number of procedures is rising globally, with the market worth over...
-
27 August 2019
Bayer AG acquires BlueRock Therapeutics
Bayer announced on August 8 that it had entered an agreement to fully acquire BlueRock Therapeutics, a biotechnology company focused on cellular therapy development.
-
21 August 2019
Continuous glucose monitoring is quickly becoming standard-of-care for diabetes patients
Knowing whether their blood glucose is rising or falling, and being able to follow patterns over time, is valuable information for people with diabetes, and would inform better treatment decisions.
-
21 August 2019
US makes strides in below-the-knee use of drug-coated balloons
Recognising that this is a market with great potential and no current competition, companies are racing to enter and monopolise the US below-the-knee drug-coated balloon catheter market.
-
5 August 2019
Allergen’s textured implant ban threatens market
Major repercussions for the breast implant market follow Allergan's global recall of its Biocell product line textured breast implants
Go Top
